CORT · Healthcare · $12.5B
After-hours $114.030.00%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
9/'26
6/'26 vs prev quarter
Among 14 Medical - Pharmaceuticals peers
Quarterly Revenue Growth
“이번 분기에서 가장 주목할 점은 신약 리포올리(Lifyorli)의 FDA 승인이에요.”
In the company's words · 2026 1분기 earnings call